Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Inetetamab

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Inetetamab on our secure patient portal to submit your prescription, upload documents and track your approval status.

Inetetamab

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Inetetamab
Generic Name (API): Inetetamab
Dosage Form & Strength: 50 mg
Route: Intravenous (IV) infusion
Drug Class: Humanised IgG1 anti-HER2 monoclonal antibody (Fc-engineered)

Manufacturer / Innovator:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Inetetamab Used For?

Inetetamab is an antibody drip for people with HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer). It is given together with the chemotherapy medicine vinorelbine. It was developed and is made in Shanghai by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc., and is sold in China as Cipterbin® (赛普汀).

China's National Medical Products Administration (NMPA) approved it in June 2020, and it was added to China's national reimbursement drug list at the end of that year. The approved use on the Chinese label is:

  • HER2-positive metastatic breast cancer, in combination with vinorelbine, for patients who have already received one or more chemotherapy regimens.

Only tumours confirmed as HER2-positive qualify: either a strong (3+) result on the immunohistochemistry (IHC) test, or a borderline (2+) IHC result with a positive FISH test. It belongs to our range of imported cancer treatments, and the decision to use it always rests with the treating oncologist.

How It Works

Some breast cancers make far too much of a growth-signal protein called HER2, which pushes the cells to divide quickly. This medicine is a humanised IgG1 monoclonal antibody that locks onto the outside part of HER2 and blocks that signal. Its Fc region (the tail of the antibody) was engineered to draw in the body's natural killer cells more strongly, a process called antibody-dependent cell-mediated cytotoxicity (ADCC), so the immune system also helps destroy the marked cancer cells.

What the Trials Showed

  • HOPES (phase 3): 341 patients in China whose metastatic breast cancer had already been treated with chemotherapy were randomised two to one to the antibody plus vinorelbine or to vinorelbine alone. In the group receiving it as their first treatment for recurrent or metastatic disease, median progression-free survival was 11.1 months with the combination against 3.3 months with vinorelbine alone, and 61.5% responded against 29.7%.
  • Weekly versus three-weekly dosing (phase 2): a 60-patient study published in 2024 compared the usual weekly schedule with a dose every three weeks, both with vinorelbine. The response rate at 24 weeks was 40.7% in each group, and safety was similar.

Recommended Dosage

The Chinese label gives this schedule:

  • First (loading) dose: 4 mg per kg body weight as an intravenous drip over at least 90 minutes
  • Then: 2 mg per kg once a week; if the first drip was well tolerated, later drips can run over 30 minutes
  • Vinorelbine: 25 mg/m² by drip on days 1, 8 and 15 of each 28-day cycle, given on the same day after the antibody
  • Preparation: each 50 mg vial is dissolved in 2.5 mL of sterile water, gently swirled (never shaken), then added to 250 mL of 0.9% sodium chloride; glucose 5% must not be used. The made-up solution is used straight away.
  • It must never be given as a fast push or bolus injection. The heart pumping score (LVEF) is checked before starting and during treatment.

The oncologist works out the exact dose from the patient's weight and decides how long treatment continues.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Boxed warning on the Chinese label: anti-HER2 antibodies can affect the heart, cause infusion and lung reactions, and harm an unborn baby. In the phase 3 study, 225 patients received the combination with vinorelbine, and the figures below compare them with patients on vinorelbine alone.

  • Heart: heart-related effects (ECG changes and palpitations) were reported in 7.11% versus 5.61%, all mild, and no symptomatic heart failure was seen. Even so, heart function is measured at baseline and usually every 3 months. If the LVEF falls by more than 10 points to below 50%, the drip is paused for at least 3 weeks, and it is stopped if the heart does not recover.
  • Infusion reactions: fever (36.44% versus 10.28%) and chills (15.56% versus 0.93%) were the most frequent, mostly mild and short-lived. Breathlessness or a marked drop in blood pressure means the drip is stopped at once, and a severe reaction means permanent stopping.
  • Blood counts: severe (grade 3–4) neutropenia occurred in 71.11% versus 53.27%, and severe low white cells in 60.44% versus 45.79%. Anaemia of any grade affected 56.89% versus 36.45%.
  • Liver and infections: raised liver enzymes were seen in 15.11% versus 8.41%, nearly all mild, and infections (mainly chest and urine) in 9.33% versus 4.67%.
  • Lungs: serious lung reactions have been reported with this class of antibody. People who are breathless at rest because of the cancer or another illness should not receive it.

Who should not use it: anyone allergic to the antibody, its other ingredients or Chinese hamster ovary (CHO) cell proteins. The label also advises against its use in people with heart failure, uncontrolled high-risk rhythm problems, angina needing medicines, significant heart valve disease, an earlier full-thickness heart attack on ECG, or poorly controlled blood pressure.

Pregnancy and breastfeeding: this type of antibody can reduce the fluid around the baby and harm lung development, so a pregnancy during treatment needs close specialist monitoring. Breastfeeding should stop during treatment. Safety under 18 years has not been established, and experience in people over 65 is limited.

How to Access Inetetamab in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Inetetamab to India?

It is imported only in the patient's own name, through the patient or a hospital, under India's rules on importing unapproved medicines. The file normally includes:

  • A prescription from the treating medical oncologist, with the patient's weight so the number of vials can be worked out
  • The breast biopsy report with the HER2 result (IHC, and FISH where the IHC was 2+), recent scans, and a note of the chemotherapy already given
  • The patient's government-issued photo ID

How is the order confirmed?

Once our team has checked the prescription and the import permit, where one is needed, has been issued.

Is it available in India?

No. CDSCO has not approved it, and Indian chemists do not stock it. It also has no approval from the US FDA or the European Medicines Agency; its only marketing approval that we could confirm is in China.

An oncologist can still ask for it through the Named Patient Program (NPP), the legal route for importing a medicine that is not registered in India for one named patient. For HER2-positive disease we also help with the Chinese tablet pyrotinib, and for some other breast cancers with sacituzumab tirumotecan.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for the powder vials to be kept and transported at 2°C to 8°C, protected from light and kept dry, so they travel under temperature-controlled shipping all the way to the hospital. Because the dose is given every week and is based on body weight, we usually send enough 50 mg vials for a full 28-day vinorelbine cycle at a time. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Patients with HER2-positive metastatic breast cancer anywhere in India can receive this antibody through a regulated import route, delivered cold to the hospital that gives the infusion, on a valid oncologist's prescription.

Delhi

Breast oncology units in Delhi run weekly day-care drips, and dispatching from New Delhi means each cold box reaches them within hours.

Mumbai

Oncologists in Mumbai can send the HER2 report and weight-based dose, and we work out the vial count before quoting.

Bangalore

For day-care centres in Bangalore, the vials are delivered before the cycle's first infusion day so the vinorelbine schedule is not delayed.

Chennai

Hospitals in Chennai receive the refrigerated vials with the temperature record attached for their pharmacy to check.

Hyderabad

Families in Hyderabad get the full cost for one 28-day cycle in writing before any order is placed.

Kolkata

Shipments to Kolkata and the north-east are packed to hold 2°C to 8°C for the longer journey.

Pune

Breast cancer patients in Pune who have finished earlier chemotherapy can use the same documented named-patient route.

Ahmedabad

The oncologist in Ahmedabad can begin by sharing the biopsy and FISH reports with our pharmacists.

Jaipur

Patients in Jaipur and across Rajasthan can have the vials sent to the hospital that gives their weekly infusion.

Chandigarh

Cancer centres in Chandigarh treating patients from Punjab, Haryana and Himachal Pradesh can receive cold-chain deliveries directly.

Lucknow

We coordinate with oncology day-care units in Lucknow so the stock is in the fridge before treatment day.

Kochi

Patients in Kochi and nearby Kerala towns can have each cycle's vials delivered to their treating hospital.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 19 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP